Global Double Barreled Antibodies Drug Sales (BLINCYTO & Removab), Pipeline Analysis (By Phase, Technology, and Indication), & Global Market Forecasts 2022

 Table of Content

1. Analyst View

2. Research Methodology

3. Double Barreled Antibodies – An Introduction

4. Double Barreled Antibodies Market Outlook to 2022
    4.1 BLINCYTO
          4.1.1 Market Potential
          4.1.2 Actual Market Size
    4.2 Removab
          4.2.1 Market Potential
          4.2.2 Actual Market Size

5. Double Barreled Antibodies Pipeline Analysis
    5.1 By Clinical Phase
    5.2 By Indication
    5.3 By Technology

6. Market Dynamics
    6.1 Drivers
          6.1.1 Rising Global Cancer Epidemics
          6.1.2 Bi-Specific Antibodies Improving the Targeting Capabilities of Traditional mAbs
          6.1.3 T-cells in Bi-Specific Antibodies Mediated Immunotherapy
          6.1.4 Increasing Demand for Bi-Specific/Double Barreled Antibodies
    6.2 Challenges
          6.2.1 Production Hurdles in Double Barreled Antibodies Development
          6.2.2 Regulatory Challenges

7. Current Status of Potential Double Barreled Antibodies in Pipeline
    7.1 BLINCYTO/Blinatumomab – Amgen Inc.
    7.2 ABT-122 – AbbVie Inc.
    7.3 MCLA-128 – Merus N.V.
    7.4 ALX-0761/M1095 - Ablynx
    7.5 MGD006/S80880 – MacroGenics, Inc.
    7.6 ZW25 – Zymeworks Inc.

8. Trends and Developments
    8.1 Bi-specific Antibody Application for Tumor Therapy
    8.2 Bi-specific Antibodies Development Against Myeloma
    8.3 Bi-specific Antibody Agreement with EpimAb Biotherapeutics
    8.4 B-specific Antibody Development against Multiple Ebola viruses

9. Strategic Collaborations in the Double Barreled Antibody Industry

10. Competitive Assessment
      10.1 Amgen Inc.
      10.2 F. Hoffman La Roche Ltd.
      10.3 AbbVie Inc.
      10.4 OncoMed Pharmaceuticals, Inc.
      10.5 Glenmark Pharmaceuticals Limited
      10.6 Xencor, Inc.
      10.7 MacroGenics, Inc.
      10.8 Aptevo Therapeutics Inc.
      10.9 Ligand Pharmaceuticals, Inc.
      10.10 Regeneron Pharmaceuticals, Inc.
      10.11 Fresenius SE & Co. KGaA
      10.12 Merus N.V.

List of Tables:

Table 4-1: Global - Potential Patients for BLINCYTO (2017)
Table 4-2: Global - Potential Patients for BLINCYTO (2020)
Table 4-3: Global - Ongoing Trials for BLINCYTO
Table 4-4: Global - Potential Patients for Removab, 2016
Table 4-5: Global - Potential Patients for Removab, 2020
Table 5-1: Global - Double Barreled Antibodies Pipeline
Table 9-1: Global - Strategic Collaborations in the Double Barreled Antibody Industry
Table 10-1: Top Companies by Double Barreled Antibodies in Pipeline, 2016
Table 10-2: Amgen Inc. - Product Portfolio
Table 10-3: Amgen Inc. - Double Barreled Antibodies in Pipeline
Table 10-4: Amgen Inc. - Key Financials (Million US$), 2013-2015
Table 10-5: F. Hoffman La Roche Ltd. - Double Barreled Antibodies in Pipeline
Table 10-6: F. Hoffman La Roche Ltd. - Key Financials (Million US$), 2014-2016
Table 10-7: AbbVie Inc. - Double Barreled Antibodies in Pipeline
Table 10-8: AbbVie Inc. - Key Financials (Million US$), 2014-2016
Table 10-9: OncoMed Pharmaceuticals, Inc. - Double Barreled Antibodies in Pipeline
Table 10-10: OncoMed Pharmaceuticals, Inc. - Key Financials (Million US$), 2014-2016
Table 10-11: Glenmark Pharmaceuticals Limited, - Double Barreled Antibodies in Pipeline
Table 10-12: Glenmark Pharmaceuticals Limited, - Key Financials (Million US$), FY 2014-2016
Table 10-13: Xencor, Inc. - Double Barreled Antibodies in Pipeline
Table 10-14: Xencor, Inc. - Key Financials (Million US$), 2014-2016
Table 10-15: MacroGenics, Inc. - Double Barreled Antibodies in Pipeline
Table 10-16: MacroGenics, Inc. - Key Financials (Million US$), 2014-2016
Table 10-17: Aptevo Therapeutics - Double Barreled Antibodies in Pipeline
Table 10-18: Ligand Pharmaceuticals, Inc. - Double Barreled Antibodies in Pipeline
Table 10-19: Ligand Pharmaceuticals, Inc. - Key Financials (Million US$), 2014-2016
Table 10-20: Regeneron Pharmaceuticals, Inc. - Double Barreled Antibodies in Pipeline
Table 10-21: Regeneron Pharmaceuticals, Inc. - Key Financials (Million US$), 2014-2016
Table 10-22: Fresenius SE & Co. KGaA - Product Portfolio
Table 10-23: Fresenius SE & Co. KGaA - Key Financials (Million US$), 2014-2016
Table 10-24: Merus N.V. - Double Barreled Antibodies in Pipeline

List of Figures:

Figure 3-1: Double Barreled Antibodies - Mechanism of Action
Figure 4-1: Global - Double Barreled Antibodies Market (Million US$), 2016-2022
Figure 4-2: Global - BLINCYTO Market (Million US$), 2015 & 2016
Figure 4-3: Global - Removab Market (Million US$), 2012 & 2013
Figure 5-1: Global - Double Barreled Antibodies Pipeline by Clinical Phase (%), 2016
Figure 5-2: Global - Double Barreled Antibodies Pipeline by Indication (%), 2016
Figure 5-3: Global - Double Barreled Antibodies Pipeline by Technology (%), 2016
Figure 6-1: Global - Cancer & Other Non-Communicable Disease Epidemics (%), 2016
Figure 10-1: Amgen Inc. - Breakup of Revenue by Geography (%), 2015
Figure 10-2: F. Hoffman La Roche Ltd. - Breakup of Group Sales by Business Segments (%), 2016
Figure 10-3: F. Hoffman La Roche Ltd. - Breakup of Group Sales by Geography (%), 2016
Figure 10-4: AbbVie Inc. - Breakup of Net Revenues by Geography (%), 2016
Figure 10-5: Glenmark Pharmaceuticals Limited, - Breakup of Revenue by Geography (%), FY 2016
Figure 10-6: Xencor, Incl. - Breakup of Revenue by Product Programs (%), 2016
Figure 10-7: Ligand Pharmaceuticals, Inc. - Breakup of Revenue by Operations (%), 2016
Figure 10-8: Ligand Pharmaceuticals, Inc. - Breakup of Royalty Revenue by Program (%), 2016
Figure 10-9: Ligand Pharmaceuticals, Inc. - Breakup of Material Sales by Use (%), 2016
Figure 10-10: Fresenius SE & Co. KGaA - Breakup of Sales by Business Segments (%), 2016
Figure 10-11: Fresenius SE & Co. KGaA - Breakup of Sales by Geography (%), 2016 

To request a free sample copy of this report, please complete the form below.

Enter captcha code*

We never share your personal data. Privacy policy